Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis's Blockbuster Gilenya Cleared For Children And Adolescents In Europe

Executive Summary

Novartis's blockbuster MS drug is now approved for children and adolescent use in the EU as well as the US, as the big pharma continues to build its MS franchise in advance of the start of generic competition to Gilenya, expected sometime after mid-2019.

 

Advertisement

Related Content

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
Novartis' Siponimod Heads Towards Regulators As Experts Question Its Effects

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel